2 Brand-New Reasons to Buy Eli Lilly Stock Right Now, and 2 Reasons to Be Cautious
As a major pharmaceutical company that is constantly innovating and developing new treatments, Eli Lilly (NYSE: LLY) is always providing investors with additional reasons to consider buying its stock.
Eli Lilly Stock Could Have a Huge Growth Catalyst in Early 2025
Eli Lilly ( LLY -1.72%) may seem like an expensive stock to invest in right now. It's trading at close to 90 times its trailing earnings. Its $720 billion market capitalization also means it's the most valuable healthcare stock in the world.
Eli Lilly & Co. stock outperforms competitors on strong trading day
Shares of Eli Lilly & Co. LLY inched 0.87% higher to $789.12 Friday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rema
Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You Trade
Eli Lilly (LLY) closed at $796.03 in the latest trading session, marking a -0.44% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.82% for the day. Elsewhere,
Eli Lilly Stock Just Got Even Sweeter. Here's Why It's Worth Buying Now
Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market. It'll take a while for the economic implications of the data to play out. One of the most important questions about the competitive prospects of Lilly against Novo Nordisk in the market for anti-obesity medicines is,
Did Eli Lilly Just Say "Checkmate" to Novo Nordisk?
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have competed for decades. In recent years, these two healthcare leaders ...
Hosted on MSN1h
EMA CHMP recommends Lilly’s Crohn’s therapy for EU approval
Committee for Medicinal Products for Human Use (CHMP) has recommended Eli Lilly’s Omvoh (mirikizumab) for approval in the ...
RFK Jr. on Ozempic, Eli Lilly's next test, and Elon Musk gets on the bandwagon: Pharma news roundup
Eli Lilly, the pharma giant behind the popular weight-loss drug Zepbound, said it plans to test obesity medications as a ...
Eli Lilly’s Mounjaro Won’t Have Separate Sleep Apnea Label in EU
Eli Lilly & Co.’s weight-loss and diabetes drug Mounjaro won’t be reclassified as a sleep apnea treatment in Europe, with ...
The Washington Post12d
Zepbound tops Wegovy for weight loss in Eli Lilly study
Shares of Eli Lilly climbed Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo ...
Eli Lilly's Zepbound beats Wegovy in head-to-head weight loss trial
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...
Verywell Health on MSN1d
Zepbound Helps People Shed More Weight Than Wegovy, According to Eli Lilly Trial
Fact checked by Nick Blackmer Eli Lilly’s Zepbound bested Novo Nordisk’s Wegovy in the first head-to-head trial comparing ...
Fierce Healthcare4d
Ro teams up with Eli Lilly to offer single-dose vials of weight loss drug Zepbound
Direct-to-consumer health and wellness company Ro will now offer access to lower-priced, single-dose vials of weight loss ...
Crain's New York4d
Eli Lilly taps Ro to help it sell a cheaper version of its weight-loss drug
Eli Lilly is partnering with the Flatiron-based telehealth company Ro to sell a cheaper version of its popular weight-loss ...
Hosted on MSN5h
EMA Panel Endorses Lilly's Omvoh for Expanded Use in Crohn's Disease
Eli Lilly LLY announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended approving its ...